New Collaboration Advances Evidence-Based Cancer Care and Oncology Decision Support
NYU Langone Health and Dana-Farber Cancer Institute have announced a strategic collaboration to co-develop Solavia Decision Suite, a next-generation oncology decision-support platform aimed at enhancing cancer care for both patients and clinicians. The partnership combines the expertise of two leading cancer care and research institutions to create a modern solution that promotes precise, evidence-based, and standardized treatment decisions at scale.
Solavia was launched internally at NYU Langone on June 30 and is now commercially available. The platform combines NYU Langone’s health IT and technology expertise with Dana-Farber’s extensive oncology experience and clinical pathway expertise. Together, the institutions have developed Solavia to support real-world clinical workflows, incorporate evolving oncology evidence, and address the needs of multidisciplinary cancer care teams.
By implementing and refining the platform within its own health system, NYU Langone has helped ensure that Solavia is practical and effective for real-world care delivery, with plans to expand its use to other healthcare organizations. The collaboration further strengthens both institutions’ leadership in advancing best practices in cancer care.
“Solavia represents an important opportunity to deploy the next generation of oncology decision support for clinicians and patients,” said Nader Mherabi, executive vice president, vice dean, and chief digital and information officer at NYU Langone. He noted that the collaboration with Dana-Farber helps translate clinical expertise into a scalable solution designed to improve consistency in care and accelerate the adoption of emerging oncology evidence.
Integrated directly into the electronic health record, Solavia gives physicians convenient access to current evidence, biomarkers, guidelines, and treatment options. The platform is designed to support high-quality patient care and research while helping standardize treatment, reduce unnecessary variation, and improve the management of oncology care pathways.
“As oncologists, we understand how rapidly cancer treatment continues to evolve. Staying up to date with the latest evidence and applying it to each patient’s unique needs can help clinicians save time and deliver the highest quality of care,” said John P. Leonard, MD, division chief of hematology and medical oncology and chief clinical officer at NYU Langone’s Perlmutter Cancer Center. “Solavia represents an important step toward making specialized clinical expertise more accessible at the point of care, empowering care teams to navigate complex treatment decisions with greater confidence and efficiency.”
The collaboration advances NYU Langone’s and Dana-Farber’s broader commitment to precision medicine and digital innovation—two key pillars of the learning health system model.
Through the co-development of Solavia, the institutions are strengthening capabilities in product governance, digital pathway development, implementation science, and clinical transformation. These capabilities have the potential to support oncology care as well as other clinical specialties in the future.
The initiative is built around a shared mission: improving health by delivering precise, personalized care plans. Any future proceeds generated through broader platform licensing will be reinvested in Solavia to support continued innovation and advance cancer care across the oncology community.
“Solavia is designed with clinicians in mind while keeping patients at the center of care,” said David Jackman, MD, medical director of clinical pathways and new business initiatives at Dana-Farber. “The platform is designed to provide care teams with evidence-based, context-aware guidance that can help make cancer treatment more personalized, coordinated, and consistent.”
Solavia also reflects a broader strategic vision shared by both institutions: moving beyond simply using digital health technologies to actively shaping the future of oncology care. Through this collaboration, NYU Langone and Dana-Farber are expanding their impact across the oncology community and helping build the digital infrastructure needed to deliver, measure, and continuously improve cancer care.
Commercialization of Solavia Decision Suite will be led by NYU Langone’s Technology Opportunities and Ventures, which will serve as the primary contact for health systems and organizations interested in learning more about the platform and exploring potential adoption opportunities.
Media Contact
Arielle Sklar
Arielle.Sklar@NYULangone.org
Business Contact
Shivany Patel
Shivany.Patel@NYULangone.org
